Incidence and Cost of Chemotherapy-Induced Adverse Drug Reactions Among Cancer Patients in a Charitable Hospital

Jeeshma Varghese; Uday Mateti; Jayarama Shetty; Malona Lilly Philip; Barma Naga Raju

doi:10.4103/jrptps.JRPTPS_68_20

Outlines

Abstract
Copyright

https://doi.org/10.4103/jrptps.JRPTPS_68_20

Incidence and Cost of Chemotherapy-Induced Adverse Drug Reactions Among Cancer Patients in a Charitable Hospital

Author(s):

Jeeshma Varghese¹,

Uday Mateti^1,*,

Jayarama Shetty²,

Malona Lilly Philip¹,

Barma Naga Raju¹

1Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Paneer, Deralakatte, Mangaluru 575018, Karnataka, India

2Department of Radiation Oncology, K.S. Hegde Medical Academy, Justice K.S. Hegde Charitable Hospital, Nitte (Deemed to be University), Deralakatte, Mangaluru 575018, Karnataka, India

Journal of Reports in Pharmaceutical Sciences:Vol. 10, issue 1; 110-7

Published online:May 31, 2021

Article type:Research Article

Received:May 27, 2020

Accepted:Mar 14, 2021

How to Cite:Jeeshma VargheseUday MatetiJayarama ShettyMalona Lilly PhilipBarma Naga RajuIncidence and Cost of Chemotherapy-Induced Adverse Drug Reactions Among Cancer Patients in a Charitable Hospital.J Rep Pharm Sci.10(1):e147100.https://doi.org/10.4103/jrptps.JRPTPS_68_20.

Abstract

Introduction: Chemotherapy-induced adverse drug reactions (ADRs) are one of the major consequences of cancer therapy that affects patients’ quality of life, outcomes of the treatment, morbidity, and mortality and increases the economic burden. The study’s objective was to evaluate the incidence, causality, severity, and preventability and to calculate the direct medical cost of chemotherapy-induced ADRs among cancer patients.
Materials and Methods: A prospective observational study was conducted for 8 months in patients above 18 years and receiving chemotherapy. ADRs were evaluated for their causality, severity, and preventability using different ADR assessment scales, and the economic burden for different ADRs was based on their direct medical costs.
Results: A total number of 230 patients were enrolled in the study, out of which 84 patients developed 148 ADRs. Patients who received chemotherapy showed a higher incidence of ADRs in 45–55 years of age group (30.95%), females (69.04%), solid tumors (92.85%), stage III (55.95%), and double regimen (61.90%). Paclitaxel and carboplatin were reported to cause most ADRs, such as anemia (14.18%) and leucopenia (6.75%). ADRs were assessed using scales. As per the WHO-UMC scale, 59.4% ADRs were possible, followed by probable (39.2%). The majority of the ADRs were mild (52%) in severity. About 41.9% reactions were probably preventable, and 3.4% were definitely preventable.
Conclusion: The overall incidence of ADRs was 36.52%. The direct medical cost incurred for the management of ADRs was 457.23 USD.

Keywords

comments

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

Metrics

Get Permission (article level)

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Jeeshma Varghese:[PubMed][Scholar]
Uday Mateti:[PubMed][Scholar]
Jayarama Shetty:[PubMed][Scholar]
Malona Lilly Philip:[PubMed][Scholar]
Barma Naga Raju:[PubMed][Scholar]